GSK and Oxford University Collaborate on Cancer Vaccines
GSK and the University of Oxford have entered a new research collaboration focused on the potential of cancer prevention through vaccination. The program, in which GSK plans to invest up to £50 million over a minimum of three years, will conduct translational research, exploring precancer biology to generate key insights on how cancer develops in humans that could inform future development of cancer vaccines.
